🔆 Beacon

← Search all trials on Beacon

Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance

Recruiting now Phase 3 NCT04578652

Run by University of Alberta · for 12 to 18 · All sexes

What this study is about

This is a 12-month, single center, three-arm parallel design, double-blind, randomized clinical trial, to compare the effects of supplemental dietary fiber and metformin (MET) alone and in combination over 12 months on glucose metabolism (insulin resistance \[IR\]), inflammation and BMI in adolescents with obesity and IR, and to assess the relationship between therapeutic intervention(s) and changes in gut microbiome composition and function. Since MET and FIBER have been shown to reduce weight and increase insulin sensitivity through distinct but overlapping mechanisms of action, our central hypothesis is that the combination of FIBER + MET will have a synergistic effect and be more effective than FIBER or MET alone in improving metabolic function (IR) and reducing BMI and inflammation in adolescents with obesity, IR and family history (FM) of T2DM. .

Who can join (things the study team will check)

✅ You may be able to join if…

🚫 You may not be able to join if…

Where this trial is running

Who to contact

Andrea M Haqq, MD, MHS · 780-492-0015 · haqq@ualberta.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT04578652.

Open the interactive checklist for this trial →

Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.

Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.